Everything below concerns Lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
The British government did not recognize the settlement as a colony for fear of provoking a Spanish attack. This delay in government oversight enabled the settlers to establish their own laws and forms of government. During this period, a few settlers gained control of the local legislature, known as the Public Meeting, as well as of most of the settlement's land and timber. The British did not appoint their first superintendent over the Belize area until 1786. Throughout the 18th century, the Spanish attacked Belize every time war broke out with Britain. The Battle of St. George's Caye was the last of such military engagements, in 1798, between a Spanish fleet and a force of Baymen and their slaves. From 3 to 5 September, the Spaniards tried to force their way through Montego Caye shoal, but were blocked by defenders. Spain's last attempt occurred on 10 September, when the Baymen repelled the Spanish fleet in a short engagement with no known casualties on either side. The anniversary of the battle has been declared a national holiday in Belize and is celebrated to commemorate the "first Belizeans" and the defence of their territory taken from the Spanish empire.
== Causes == Most presentations of CTS have no known disease cause (idiopathic). The association of other factors with CTS is a source of notable debate. It is important to distinguish factors that provoke symptoms and factors that are associated with seeking care from factors that make the neuropathy worse. Genetic factors are believed to be the most important determinants of who develops carpal tunnel syndrome. In other words, one's wrist structure seems programmed at birth to develop CTS later in life. A genome-wide association study (GWAS) of carpal tunnel syndrome identified 50 genomic loci significantly associated with the disease, including several loci previously known to be associated with human height. Some other factors that contribute to carpal tunnel syndrome are conditions such as diabetes, alcoholism, vitamin deficiency or toxicity as well as exposure to toxins. Conditions such as these don't necessarily increase the interstitial pressure of the carpal tunnel. One case-control study noted that individuals classified as obese (BMI >29) are 2.5 times more likely than slender individuals (BMI <20) to be diagnosed with CTS. It is not clear whether this association is due to an alteration of pathophysiology, a variation in symptoms, or a variation in care-seeking.
=== Networking === Service Improvement Plan, a former program to provide a defined level of basic telephone service to all Canadians Standard Interchange Protocol, in library systems System Information Packet, in the DMX512 standard for stage lighting control Session Initiation Protocol, a signaling protocol most commonly used in Internet Telephony
Sources: en.wikipedia.org
==== Domestic research and experimentation tax deduction ==== The law allows full expensing of domestic research and experimentation expenditures for tax years beginning on or after January 1, 2025. The law allows businesses to hold an election to amortize domestic research and experimentation expenditures that are otherwise capitalized (other than property that would be depreciated or depleted) over a five-year period. The law allows certain businesses to elect to claim a tax deduction for unamortized domestic research and experimentation costs in the first tax year beginning after 2024 or ratably over a two-year period. The law allows certain small businesses to retroactively expense its domestic research and experimentation costs for tax years that began on or after January 1, 2022.
Concurrently, the Bureau of Longitude Studies and the Observatory were undertaking a comprehensive review of his extensive barometric and astronomical measurements. Furthermore, artists had been commissioned to commence the replication of his botanical sketches and illustrations of ancient Indian monuments. At this time, Napoleon Bonaparte was the only person in Europe with greater fame than Humboldt. Their sole meeting was unsuccessful, with Napoleon responding coldly, possibly viewing Humboldt as a politically suspect foreigner. Despite this, Napoleon granted a pension to Bonpland but later attempted to expel Humboldt from Paris on suspicion of espionage. Paris, despite political changes since Humboldt’s departure, was now the leading center of science, offering exceptional resources and collaborators. Humboldt chose to remain, preferring Paris’s intellectual and social environment over Berlin, which he considered unappealing. He immersed himself in work, organizing his extensive collections and distributing specimens to various institutions. Bonpland kept the most complete set of plant specimens, with other collections sent to major European botanical gardens. Humboldt’s dedication to processing and publishing his scientific findings required several years of intense effort. During their American expedition, Alexander von Humboldt and Aimé Bonpland encountered numerous challenges and hardships, many of which were described in Humboldt’s Voyage aux régions équinoxiales du Nouveau Continent and related works.
=== Post-injection delirium/sedation syndrome === Post-injection delirium/sedation syndrome (PDSS) is a serious adverse event previously considered specific to olanzapine pamoate (Zyprexa Relprevv) among LAI antipsychotics. PDSS is characterized by heavy sedation, possible coma, and/or delirium following injection, believed to result from inadvertent intravascular drug entry. Early industry-sponsored analyses of clinical trial and post-marketing databases found no cases of PDSS in patients receiving paliperidone palmitate across 10 completed trials (3,817 subjects, 33,906 injections), leading to the conclusion that PDSS was not associated with paliperidone palmitate. However, a 2024 post-marketing case report published in the Journal of Clinical Psychopharmacology documented a case of PDSS following paliperidone palmitate administration. A 48-year-old male patient with bipolar affective disorder received two 234 mg loading doses of paliperidone palmitate (Invega Sustenna) one week apart. Two days after the second injection, he developed trembling, rigidity, weakness, and drowsiness. His symptoms worsened over the following days to include slurred speech and difficulty walking and talking. The authors recommended routine measurement of baseline antipsychotic blood levels as part of long-acting injectable management to help identify patients at elevated risk.
==== Illegal marketing of gabapentin for off-label uses settlement (2004) ==== In 1993, the Food and Drug Administration (FDA) approved gabapentin only for treatment of seizures. Warner–Lambert, which merged with Pfizer in 2000, used continuing medical education and medical research, sponsored articles about the drug for the medical literature, and alleged suppression of unfavorable study results, to promote gabapentin. Within five years, the drug was being widely used for off-label uses such as treatment of pain and psychiatric conditions. Warner–Lambert admitted to violating FDA regulations by promoting the drug for pain, psychiatric conditions, migraine, and other unapproved uses. In 2004, the company paid $430 million in one of the largest settlements to resolve criminal and civil health care liability charges. It was the first off-label promotion case successfully brought under the False Claims Act. A Cochrane review concluded that gabapentin is ineffective in migraine prophylaxis. The American Academy of Neurology rates it as having unproven efficacy, while the Canadian Headache Society and the European Federation of Neurological Societies rate its use as being supported by moderate and low-quality evidence.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.